论文部分内容阅读
目的 :为进一步探讨刺五加对实验性肝癌发病的干预作用及其可能机理。方法 :43只雄性大鼠被随机分成 3组①正常对照组 :喂普通饲料 ② 3′-MeDAB组 :喂含 0 0 6 % 3′-MeDAB饲料 10周 ③刺五加组 :除致癌剂外另加入刺五加 (4 .5g/kg饲料 ) ,历时 2 0周。实验过程中所有动物均自由进食及饮水。 结果 :刺五加组较 3′ -MeDAB组 :①外周血液及肝组织中PAI- 1含量明显减少 (P <0 0 5 )。②肝细胞周期时相G0 /G1比率增加 (P <0 0 1) ,S期和G2 M期比率减少 (P <0 0 1) ,PI和DI减低 (均P <0 0 1) ,③肝细胞rasp2 1荧光指数减低 (P <0 0 5 ) ,④免疫组化PCNA阳性表达率降低。⑤光镜及电镜检测均显示有一定程度减轻。结论 :上述结果提示刺五加适于被开发为常规抗癌辅助药物
Objective : To further investigate the intervention effect of Acanthopanax on experimental liver cancer and its possible mechanism. METHODS: Forty-three male rats were randomly divided into three groups: 1 normal control group: normal diet 2 3′-MeDAB group: fed 0 0 6 % 3′-MeDAB diet for 10 weeks 3 Acanthopanax group: except for carcinogenic agents Another addition of Acanthopanax (4.5g/kg feed) lasted for 20 weeks. All animals were allowed to eat and drink freely during the experiment. RESULTS: Compared with 3′-MeDAB group:1, the content of PAI-1 in peripheral blood and liver tissue was significantly decreased (P<0 05). 2 The ratio of G0/G1 in hepatic cell cycle increased (P < 0 01), the ratio in S and G2 M phase decreased (P <0 01), PI and DI decreased (P <0 01), 3 liver The fluorescence index of rasp21 decreased (P < 0.05), and the positive rate of PCNA immunohistochemistry decreased. 5 Both light and electron microscopy showed a certain degree of reduction. Conclusion: The above results suggest that Acanthopanax is suitable for being developed as a conventional anti-cancer adjuvant drug.